Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
About Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc. (Nasdaq: COLL) is a leading specialty pharmaceutical company committed to improving the lives of patients living with chronic pain and other serious medical conditions. Headquartered in Stoughton, Massachusetts, the company leverages its proprietary DETERx® technology platform to develop and commercialize next-generation, abuse-deterrent medications. Collegium's innovative approach addresses the growing public health concerns surrounding the misuse and abuse of prescription drugs, particularly opioids, while maintaining efficacy for patients who require long-term pain management solutions.
Core Business and Product Portfolio
At the heart of Collegium’s operations is its portfolio of abuse-deterrent medications designed to mitigate risks associated with non-medical use. The company’s flagship product, Xtampza ER®, is an extended-release, oral formulation of oxycodone that employs DETERx® technology to maintain its safety and efficacy profile even when subjected to physical manipulation such as crushing or dissolving. Collegium also markets the Nucynta® franchise, which includes both immediate-release and extended-release formulations of tapentadol, used for managing acute and chronic pain.
In 2024, Collegium expanded its portfolio through the acquisition of Ironshore Therapeutics, adding Jornay PM®, a unique evening-dosed ADHD medication, to its offerings. This strategic move established the company’s presence in the growing neuropsychiatry market, diversifying its revenue streams and positioning it for long-term growth.
Technological Innovation: The DETERx® Platform
Collegium’s proprietary DETERx® technology is a cornerstone of its product development strategy. This platform enables the creation of extended-release formulations that are resistant to common forms of abuse, such as chewing, crushing, and dissolving. By integrating this technology into its medications, Collegium addresses two critical needs: providing effective pain relief for patients and reducing the potential for misuse and abuse. The DETERx® platform is protected by a robust portfolio of U.S. and international patents, underscoring Collegium’s commitment to innovation and intellectual property protection.
Strategic Growth and Market Position
Collegium has established itself as a key player in the specialty pharmaceutical industry through a combination of innovation, strategic acquisitions, and disciplined capital deployment. The company’s focus on responsible pain management has earned it a strong reputation among healthcare providers and patients alike. Its recent acquisition of Ironshore Therapeutics not only diversifies its product portfolio but also enhances its market presence in the neuropsychiatry segment.
With a strong financial foundation and a commitment to operational excellence, Collegium is well-positioned to navigate the challenges of a highly regulated industry. The company continues to invest in research and development, aiming to expand its portfolio and address unmet medical needs in both pain management and neuropsychiatry.
Commitment to Responsible Pain Management
Collegium is dedicated to advancing science-based solutions for pain management while prioritizing patient safety. The company actively engages with healthcare providers, policymakers, and the broader medical community to promote the responsible use of opioid medications. By combining innovative technology with a patient-centered approach, Collegium aims to set new standards in the treatment of chronic pain and other serious medical conditions.
Conclusion
Collegium Pharmaceutical Inc. exemplifies the integration of innovation, responsibility, and strategic growth in the pharmaceutical industry. Through its proprietary DETERx® technology, diverse product portfolio, and commitment to addressing critical public health challenges, the company continues to make meaningful contributions to the healthcare landscape. As it expands into new therapeutic areas like neuropsychiatry, Collegium remains focused on its mission to improve patient outcomes and create long-term value for stakeholders.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in the 24th Annual Needham Healthcare Conference, which will be held virtually from April 7-10, 2025. The company's management will engage in a fireside chat scheduled for Tuesday, April 8, 2025, at 9:30 a.m. ET.
The fireside discussion will be accessible through a live webcast on the Investors section of Collegium's website. Interested parties can view the presentation at https://ir.collegiumpharma.com, and a replay will remain available on the company's website for 90 days following the event.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its upcoming presentation of four posters featuring real-world patient data from its pain management portfolio at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting in Austin, TX, from April 3-6, 2025.
A notable highlight is their poster on 'Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids,' which has been selected as a top abstract and will be published in AAPM's Pain Medicine Journal. The presentations will focus on their key products, including BELBUCA® (buprenorphine buccal film) and Xtampza® ER (oxycodone), both prescribed for severe pain management requiring daily, long-term opioid treatment.
Dr. Thomas Smith, Chief Medical Officer, emphasized the significance of presenting meaningful real-world data for healthcare professionals treating pain patients, reinforcing Collegium's position as a leader in responsible pain management.
Collegium Pharmaceutical (COLL) announced significant changes to its Board of Directors and executive leadership team. Founder and Chairman Michael Heffernan and Board Member Gwen A. Melincoff will retire at the Annual General Meeting on May 15, 2025. Gino Santini, current Lead Independent Director, will become Chairman, while Dr. Carlos Paya will be nominated to the Board.
The company also appointed three new executive leaders: David Dieter as Executive VP and General Counsel, Jane Gonnerman as Executive VP of Strategy and Corporate Development, and Dean J. Patras as Chief People Officer. These appointments come as Collegium enters a new growth phase focused on accelerating momentum for Jornay PM, maximizing its pain portfolio, and strategic capital deployment.
Collegium Pharmaceutical (Nasdaq: COLL) announced two poster presentations featuring real-world data for its ADHD treatment Jornay PM (methylphenidate HCl) at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference in Chicago from March 10-13, 2025.
The presentations, which will showcase real-world benefits of Jornay PM as a therapeutic option for the ADHD community, will be displayed in the Riverside Center Exhibit Hall during specific exhibition hours on March 10-11, 2025. Chief Medical Officer Thomas Smith emphasized the company's commitment to providing differentiated medicines for serious medical conditions.
The PR highlights that ADHD is one of the most common childhood psychiatric conditions, typically diagnosed in childhood and potentially continuing into adulthood, with symptoms including attention difficulties, impulsive behaviors, and hyperactivity, particularly during early morning routines.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its upcoming participation in three major healthcare investor conferences in March 2025. The company's management will engage in investor meetings at the Leerink Partners 2025 Global Healthcare Conference on March 11, the Jefferies Biotech on the Beach Summit on March 12, and the Barclays 27th Annual Global Healthcare Conference on March 13.
Collegium Pharmaceutical reported strong financial results for Q4 and full-year 2024. The company achieved record quarterly revenue of $181.9 million (up 22% YoY) and full-year revenue of $631.4 million (up 11% YoY). Q4 GAAP net income was $12.5 million with record adjusted EBITDA of $107.7 million.
Key product performance included Jornay PM with Q4 net revenue of $29.3 million and pro forma full-year revenue of $100.7 million, showing 29% YoY prescription growth. Belbuca achieved record quarterly revenue of $55.2 million (up 12% YoY), while Xtampza ER posted record revenue of $51.5 million (up 6% YoY).
The company ended 2024 with $162.8 million in cash and equivalents, after completing the $200 million Ironshore Therapeutics acquisition and executing $60 million in share repurchases.
Collegium Pharmaceutical (Nasdaq: COLL) has scheduled its fourth quarter and full-year 2024 financial results announcement for Thursday, February 27, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. Investors can access the call via U.S. dial-in (877) 407-8037 or International dial-in (201) 689-8037. An audio webcast will be available on the company's website investor section and will remain accessible for replay approximately two hours after the event.
Collegium Pharmaceutical (Nasdaq: COLL) has appointed Nancy S. Lurker to its Board of Directors, effective February 4, 2025. Lurker brings significant expertise in commercial growth and strategic acquisitions, having most recently served as President and CEO of EyePoint Pharmaceuticals until 2023, where she now holds the position of Executive-Vice Chair.
Her extensive experience includes roles as President and CEO of PDI, Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals, and President and CEO of ImpactRx. She currently serves on multiple boards, including Alkermes plc and Altasciences, , and advisory boards for Novo Holdings and Stanford Medicine's Master of Science program.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its 2025 financial guidance, projecting product revenues between $735-750 million and adjusted EBITDA of $435-450 million. The company expects Jornay PM, their ADHD treatment, to generate over $135 million in net revenue, positioning it as their primary growth driver.
The company's adjusted operating expenses are anticipated to be between $220-230 million. Recent highlights include completing the Ironshore integration, accelerating Jornay PM prescriptions during the 2024 back-to-school season, and executing a share repurchase program worth $60 million under a $150 million authorization, including $25 million in Q4 2024 and $35 million through an accelerated program in May 2024.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in two upcoming investor conferences. The company will engage in fireside chats at the Jefferies London Healthcare Conference on November 19, 2024, at 1:30 p.m. GMT and the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024, at 1:00 p.m. ET. Both sessions will be accessible via webcast through the company's investor relations website, with recordings available for 90 days post-presentation.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
What does Collegium Pharmaceutical Inc. specialize in?
What is the DETERx® technology platform?
What are Collegium’s key products?
How does Collegium address opioid misuse and abuse?
What was the significance of the Ironshore Therapeutics acquisition?
Where is Collegium Pharmaceutical headquartered?
How does Collegium differentiate itself in the pharmaceutical industry?
What markets does Collegium operate in?
